Concepedia

Publication | Open Access

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

DOIFull Paper Access

856

Citations

26

References

2013

Year

Sharon Walmsley, Antonio Antela, Nathan Clumeck, Dan Duiculescu, Andrea Eberhard, Félix Gutiérrez, Laurent Hocqueloux, Franco Maggiolo, Uriel Sandkovsky, Catherine Granier,
New England Journal of Medicine

Abstract

Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine. (Funded by ViiV Healthcare; SINGLE ClinicalTrials.gov number, NCT01263015 .).

References

YearCitations

Page 1